about
Natalizumab for relapsing remitting multiple sclerosisNatalizumab for relapsing remitting multiple sclerosisN-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes.Cognitive and behavioural correlates of different domains of psychological adjustment in early-stage multiple sclerosis.The intrathecal CD163-haptoglobin-hemoglobin scavenging system in subarachnoid hemorrhage.Relapse in multiple sclerosis.CNS inflammation other than multiple sclerosis: how likely is diagnosis?Blood-derived dendritic cells in an acute brain injury.A web-based tool for personalized prediction of long-term disease course in patients with multiple sclerosis.Structural basis for inflammation-driven shedding of CD163 ectodomain and tumor necrosis factor-α in macrophages.Stress and exacerbations in multiple sclerosis: whether stress triggers relapses remains a conundrum.Mannose receptor expression specifically reveals perivascular macrophages in normal, injured, and diseased mouse brain.CD163-positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation.What is the blood-brain barrier (not)?Pearls & Oy-sters: resolution of hemichorea following endarterectomy for severe carotid stenosis.Haemoglobin scavenging after subarachnoid haemorrhage.Heme-Hemopexin Scavenging Is Active in the Brain and Associates With Outcome After Subarachnoid Hemorrhage.Risk knowledge of people with relapsing-remitting multiple sclerosis - Results of an international surveyHearing impairment after subarachnoid hemorrhageBiochemical indices of renal osteodystrophy in dialysis patients on the island of MaltaCerebrospinal fluid analysis in the 2010 revised McDonald's multiple sclerosis diagnostic criteriaHaptoglobin genotype and outcome after spontaneous intracerebral haemorrhageHaptoglobin genotype and outcome after aneurysmal subarachnoid haemorrhageHaptoglobin genotype and aneurysmal subarachnoid hemorrhage: Individual patient data analysisHaemoglobin causes neuronal damage in vivo which is preventable by haptoglobinDefining causality in COVID-19 and neurological disorders
P50
Q24235861-55FA9F10-26D0-48BD-8ECD-962862E0FEF8Q24241982-16A07D8F-8697-4ED3-B04A-1A62E846A23FQ33882739-63A59CD1-5F49-4164-8826-7560258FDD57Q34138375-5B52F1A5-2B1B-4BAF-B600-9D74D9F9C0ECQ36141369-543E5033-8565-43AF-8B39-8EBB4F6C8DE6Q38420493-FAC04524-8417-4458-82E4-1DCDA9FFB693Q38530271-016ACFD3-90FC-4D43-8BFA-75960ADE14D3Q40399923-C66B4FAC-7B74-4E6A-8172-B4F4E7ED7900Q41433436-2BFB9BBF-13F0-4E9A-837C-64FC02C1D8B7Q41863389-CFAB1A95-D316-4407-A638-F88FA4CB5753Q43138128-B9C9B519-9F37-45EE-94EF-7D29059ADB06Q45147509-71DAC57A-CABD-45F7-AD3A-63E14DC91675Q46450925-231D5B4E-570D-40AA-832C-F5E36CE83BA6Q48350383-BB9370F1-FA69-4335-9B79-3C6DD4584166Q48810237-82879CF6-9251-4E3F-9A98-493A995C0D38Q51037998-5A2CA00D-9D16-466B-8CA8-B2B4781BA751Q52144779-CA0A5EC9-7192-470D-8AF8-76DF557A9D00Q60049114-7810CB0C-6392-4B09-AEC3-A772D7FFAA74Q64262821-204DF673-223E-4BD4-AB07-78E318386E5EQ81162180-BE10021E-65AB-4A46-A311-4350873A4914Q84590553-F18EFC86-B93D-4B34-9E58-5B3158A8C98EQ92562513-1A3BA3DA-9BE0-428D-92BE-3186CA5AFB21Q92641612-5200B00F-C816-4947-9EC1-8A4B060AACEBQ92885460-0C7871E9-940B-40B7-B1A5-0CBFECF0E72FQ94453638-8DFAB264-94FD-41F4-95F6-6D3F0413E41AQ96171265-7D761CB0-3F8F-4A33-8712-64DEF16A6D3D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ian Galea
@ast
Ian Galea
@en
Ian Galea
@es
Ian Galea
@nl
Ian Galea
@sl
type
label
Ian Galea
@ast
Ian Galea
@en
Ian Galea
@es
Ian Galea
@nl
Ian Galea
@sl
prefLabel
Ian Galea
@ast
Ian Galea
@en
Ian Galea
@es
Ian Galea
@nl
Ian Galea
@sl
P1053
B-7997-2011
P106
P31
P3829
P496
0000-0002-1268-5102